Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Michelle Mahler"'
Autor:
Anthony Mato, Jordan Jahnke, Pengxiang Li, Maneesha Mehra, Vrushabh P. Ladage, Michelle Mahler, Scott Huntington, Jalpa A. Doshi
Publikováno v:
Haematologica, Vol 103, Iss 10 (2018)
Externí odkaz:
https://doaj.org/article/b8a1f9385bde4f569d975d3305505fa3
Autor:
Jennifer R. Brown, Javid Moslehi, Susan O’Brien, Paolo Ghia, Peter Hillmen, Florence Cymbalista, Tait D. Shanafelt, Graeme Fraser, Simon Rule, Thomas J. Kipps, Steven Coutre, Marie-Sarah Dilhuydy, Paula Cramer, Alessandra Tedeschi, Ulrich Jaeger, Martin Dreyling, John C. Byrd, Angela Howes, Michael Todd, Jessica Vermeulen, Danelle F. James, Fong Clow, Lori Styles, Rudy Valentino, Mark Wildgust, Michelle Mahler, Jan A. Burger
Publikováno v:
Haematologica, Vol 102, Iss 10 (2017)
The first-in-class Bruton’s tyrosine kinase inhibitor ibrutinib has proven clinical benefit in B-cell malignancies; however, atrial fibrillation (AF) has been reported in 6–16% of ibrutinib patients. We pooled data from 1505 chronic lymphocytic l
Externí odkaz:
https://doaj.org/article/f2985c5022894b3aa2128bf6561c3340
Autor:
Ashley A. Hart, Stewart L. Fisher, Christina S. Henderson, Scott J. Eron, David A. Proia, Roy M. Pollock, Prasoon Chaturvedi, James A. Henderson, S Perino, B. T Kreger, Christopher G. Nasveschuk, Adam S. Crystal, Andrew C. Good, Roman V. Agafonov, Marta Isasa, B Class, Michelle Mahler, R. J Kirby
Publikováno v:
Hematological Oncology. 39
Autor:
Katrina L. Jackson, Roman V. Agafonov, Mark W. Carlson, Prasoon Chaturvedi, David Cocozziello, Kyle Cole, Richard Deibler, Scott J. Eron, Andrew Good, Ashley A. Hart, Minsheng He, Christina S. Henderson, Hongwei Huang, Marta Isasa, R. Jason Kirby, Linda Lee, Michelle Mahler, Moses Moustakim, Christopher G. Nasveschuk, Michael Palmer, Laura L. Poling, Roy M. Pollock, Matthew Schnaderbeck, Stan Spence, Gesine K. Veits, Jeremy L. Yap, Ning Yin, Rhamy Zeid, Adam S. Crystal, Andrew J. Phillips, Stewart L. Fisher
Publikováno v:
Cancer Research. 82:ND09-ND09
Introduction: The chromatin factor BRD9 is a genetic dependency in some cancers, often referred to as SMARCB1-perturbed cancers. Two types of genetic alterations result in SMARCB1 perturbation: SS18-SSX gene fusion and SMARCB1 loss-of-function mutati
Autor:
Sagar Lonial, Shambavi Richard, Jeffrey V Matous, Andrew J. Yee, Urvi Shah, Neha Mehta-Shah, Thomas Martin, Eli Muchtar, Sikander Ailawadhi, Paul G. Richardson, Manisha Bhutani, Samantha Perino, Jason Kirby, Roman V. Agafonov, Prasoon Chaturvedi, Bradley Class, Matthew Schnaderbeck, Michael R. Palmer, Cathleen Gorman, Oliver Schoenborn-Kellenberger, Amanda Hoerres, Stewart L. Fisher, Roy M. Pollock, Adam Crystal, Michelle Mahler, Jesus Bardeja
Publikováno v:
Cancer Research. 82:CT186-CT186
Introduction: CFT7455 is a highly potent and novel Ikaros Family Zinc Finger Protein 1/3 (IKZF1/3) degrader. In xenograft models, CFT7455 has more potent IKZF1/3 degradation compared to other degraders. Early observations from the FIH clinical trial
Autor:
James A. Henderson, Scott J. Eron, Andrew Good, R Jason Kirby, Samantha Perino, Roman V. Agafonov, Prasoon Chaturvedi, Bradley Class, David Cocozziello, Ashley A. Hart, Christina S. Henderson, Marta Isasa, Brendon Ladd, Matt Schnaderbeck, Michelle Mahler, Adam S. Crystal, Roy M. Pollock, Christopher G. Nasveschuk, Andrew J. Phillips, Stewart L. Fisher, David A. Proia
Publikováno v:
Cancer Research. 82:ND13-ND13
Introduction: Ikaros family zinc finger protein 1 and 3 (IKZF1/3) are essential transcription factors (TF) for terminal differentiation of B and T cells. Depletion of IKZF1/3 inhibits the growth of multiple myeloma (MM) cells, confirming their depend
Autor:
Javid Moslehi, Simon Rule, Martin Dreyling, Susan O'Brien, Amulya Bista, Rudolph Valentino, Stephen Chang, Steven Coutre, Michelle Mahler, Thorsten Graef, Huiying Yang, Marie Sarah Dilhuydy, Rama Vempati, Paolo Ghia, Paula Cramer, John C. Byrd, Michael S. Ewer, Florence Cymbalista, Steven P. Treon, Jennifer R. Brown, Graeme Fraser, Emily Y. Liu, Ulrich Jaeger, Jan A. Burger, Vijay Reddy, Tait D. Shanafelt, Lisa Boornazian
Publikováno v:
British Journal of Haematology
Summary Ibrutinib, a Bruton tyrosine kinase inhibitor, is approved for treatment of various B‐cell malignancies. In ibrutinib clinical studies, low‐grade haemorrhage was common, whereas major haemorrhage (MH) was infrequent. We analysed the incid
Autor:
Luis Palmer, Sergio Araujo, Alvaro Gomez Diaz, David Gómez-Almaguer, Carlos S. Chiattone, Yen-Wen Chen, Lori Parisi, Danielle Leão Cordeiro de Farias, Carolina Pavlovsky, Kenny Mauricio Galvez-Cardenas, Michelle Mahler, Gerardo Machnicki, Ana Lisa Basquiera, Paula Barreyro, Elena J Tuna-Aguilar, Jennifer H. Lin
Publikováno v:
Hematology (Amsterdam, Netherlands). 25(1)
To describe chronic lymphocytic leukemia (CLL) treatment patterns and patient outcomes in Latin America.This chart review study (NCT02559583; 2008-2015)evaluated time to progression (TTP) and overall survival (OS) outcomes among patients with CLL who
Autor:
Shanisha Gordon-Mitchell, Aditi Shastri, Srinivas Aluri, Weng Lang Yang, Amit Verma, Chandan Guha, Diego Adrianzen-Herrera, Tushar D. Bhagat, Gary Eichenbaum, Gaurav Choudhary, Nandini Ramachandra, Hui Zhang, Britta Will, Michelle Mahler, Ulrich Steidl
Publikováno v:
Leukemialymphoma. 61(10)
Thrombocytopenia remains a challenge in myeloid malignancies, needing safer and more effective therapies. JNJ-26366821, a pegylated synthetic peptide thrombopoietin (TPO) mimetic not homologous to endogenous TPO, has an in-vitro EC50 of 0.2 ng/mL for
Autor:
Asher Chanan-Khan, Olga Samoilova, Charles Phelps, Michelle Mahler, Javier Loscertales, Dirceu Villa Villa, Ann Janssens, Andre Goy, M. Salman, Simon Rule, Claes Karlsson, Miguel A. Pavlovsky, Graeme Fraser, Angela Howes, Alexander Pristupa, Steven Sun, Marie-Sarah Dilhuydy, Abraham Avigdor, Paula Cramer, Panagiotis Panagiotidis, Nancy L. Bartlett, Sriram Balasubramanian, Jiří Mayer, Fatih Demirkan, R. Santucci Silva, Sebastian Grosicki, Halyna Pylypenko, Michael Hallek
Publikováno v:
Leukemia
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
We report follow-up results from the randomized, placebo-controlled, phase 3 HELIOS trial of ibrutinib+bendamustine and rituximab (BR) for previously treated chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) without deletion 17p. Ov